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Summary 
The human OX-40  cell surface antigen  is  a  CD4 + T  cell activation marker that  acts  as  a 
costimulatory receptor and is a member of the nerve growth factor receptor/tumor necrosis factor 
(TNF) receptor family. Using a soluble form of the receptor, the extracellular region fused with 
human immunoglobulin Fc, we expression cloned the human OX-40 ligand cDNA from a library 
derived from an activated B lymphoblastoid cell line MSAB.  The encoded protein is identified 
as gp34,  a type II transmembrane antigen previously known to be expressed only by human 
T cell lymphotropic virus 1-infected cells. We describe gp34 as a new member of the TNF family, 
and find that the recombinant ligand expressed in COS cells costimulates phorbol myristate acetate, 
phytohemagglutinin, and anti-CD3-induced CD4 + T  cell proliferation. 
T 
he human 106/OX-40 antigen is a 50-kd cell surface gly- 
coprotein  expressed primarily on  activated CD4 +  T 
cells  (1-4,  and Godfrey, W.  R.,  D.  Buck,  E  F.  Fagnoni, 
M. A. Harara, and E. G. Engleman, manuscript submitted 
for publication). The antigen is not expressed on freshly iso- 
lated PBMC or on purified subpopulations of PBMC,  in- 
cluding B cells, monocytes, dendritic cells, CD4 § , or CD8 + 
T cells. Few tumor cell lines have been shown to express this 
antigen, and those that are positive are dim with the excep- 
tion of certain HTLV-I-infected T cell lines. The cDNA en- 
coding the human OX-40 antigen has been cloned (3, 4, and 
Godfrey, W. R. et al., manuscript submitted for publication) 
and shown to be a member of the nerve growth factor receptor 
(NGFR)U  TNFR gene family (5-7),  which also includes 
the fas/APO-1, CD40, CD27, CD30, and 4-1BB/ILA anti- 
gens. The known functions of the members of this family 
include the regulation  of growth  control,  apoptosis,  and 
differentiation (7). 
The activation and growth of CD4 § T cells is controlled 
by contextual costimulatory signals  in addition to ligation 
of the antigen receptor (8,  9).  It is becoming increasingly 
clear that  there are multiple pathways in  addition  to  the 
B7/CD28 interaction that can mediate costimulation (10, 11). 
However, relatively little is known about the molecular iden- 
tity, tissue distribution, and signalling mechanisms of these 
other pathways. It is interesting to note that several members 
of the NGFR/TNFR  family have been shown  to  act  as 
costimulatory receptors, including CD27 (12),  CD30 (13), 
4-1BB (14, 15), and fas (16). We have recently demonstrated 
that the human 106/OX-40 antigen can also act as a costimula- 
tory receptor for CD4 § T cells, by cross-linking the antigen 
with either soluble or immobilized L106 antibody (Godfrey, 
W.  R.  et al.,  manuscript submitted for publication). 
Putative ligands have been described for all the reported 
NGFR/TNFR family members, except for the OX-40 an- 
tigens (7). The reported ligands have been shown to consti- 
tute a family of molecules related to TNF, and can exist in 
membrane-bound forms. The identity of the natural human 
OX-40 ligand thus became a high priority in the attempt 
to better understand the function of the 106/human OX-40 
receptor. Here we report the generation of a soluble receptor 
construct, the detection of ligand on activated EBV-trans- 
formed B cells, the identification of a human OX-40 ligand 
as gp34, and the characterization of the recombinant ligand 
as a costimulator of CD4 §  T  cell proliferation. 
Materials and Methods 
mAbs.  The mAbs OKT3 (CD3), leu2a (CD8), 63D3 (CD14), 
leulla (CD16), and L243 (HLA-DR) were prepared and purified 
in this hboratory, mAb L106-PE conjugate was produced by Becton 
Dickinson Immunocytometry Systems (San Jose, CA). 
Peripheral Blood Cells, Cell Lines, and Activation.  PBMC were 
isolated from healthy volunteer donors by using Ficoll-Hypaque 
density gradients. T cells were further purified by rosetting with 
neuraminidase-treated SRBC. B cells were further purified by pas- 
sage of the nonrosetting cells over a Percoll gradient and collection 
of the high density fraction, foLlowed  by depletion ofCD3 (OKT3), 
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netic beads (Dynal, Inc., Great Neck, NY). Monocytes were pre- 
pared by passage of PBMC over a Percoll gradient  and recovery 
of the low density fraction. The cell line MSAB, an EBV-transformed 
B cell line, was originally derived at Cetus Corp. (Berkeley, CA). 
THP-1, a monocytic cell line, was obtained from American Type 
Culture Collection (Rockville, MD). The MT-2 and HUT-102 cell 
lines were obtained from the laboratory of Dr.  Steven Foung of 
Stanford University. B cells, T cells, MSAB, and THP-1 were acti- 
vated for 3 d with 5 ng/ml PMA (Sigma Chemical Co., St. Louis, 
MO) and 500 ng/ml ionomycin (Calbiochem-Novabiochem Corp., 
La Jolla,  CA). 
Fusion Proteins and Immunofluorescence.  Soluble 106 antigen was 
constructed  as a fusion protein,  which consisted of the extracel- 
lular region of the 106Ag fused to the C region of the human Ig 
H chain IgG1 (106-Ig). The Ig-encoding fragment of 4-1BB-Ig (17), 
which contains the hinge, CH2, and CH3 domains, was subcloned 
into  the  106 cDNA-containing  plasmid.  The Ig fragment  was 
released by digestion with BamHI, falling in with Klenow poly- 
merase, and subsequent digestion with EagI. This generated a frag- 
ment with blunt and NotI compatible  ends, which was ligated 
into a SmaI/NotI-digested 106 plasmid. Soluble fusion proteins 
were produced by transient transfections of COS-7 cells, and the 
supematants were recovered after 7 d. Control fusion proteins were 
produced by parallel transfections of the CDM7B-  vector (con- 
taining CD5 signal-Ig) (18), and the 4-1BB-Ig vector. Cells were 
stained with fusion protein  in the presence of 10% goat serum 
and 5% fetal bovine serum, and binding was visualized by staining 
with PE-goat anti-human  IgG, 3' chain specific (American Qualex 
Antibodies & Immunochemicals Co., La Mirada, CA). Flow cytom- 
etry was performed using  a Profile II (Coulter,  Hialeah,  FL). 
cDNA Cloning.  RNA was isolated from day 3 PMA/ionomycin 
activated MSAB cells, cDNA was synthesized (19) using  super- 
script reverse transcriptase (GIBCO BILL, Gaithersburg, MD) and 
an oligo dT primer. The blunted cDNA was ligated to nonself- 
complementary BstXI adaptors and passed over a Sephacryl S-500 
sizing column to remove unligated adaptors and small fragments. 
The linkered cDNA was then ligated into the pcDNA-I expression 
vector (Invitrogen, San Diego, CA), and electroporated into Esche- 
richia coli strain MC1061/P3  (20, 21). 
Subconfluent  COS-7  cells were electroporated  (22) with the 
plasmid cDNA library. After 48 h of culture, calls were recovered 
from the plates with PBS-EDTA solution and stained with 106-Ig. 
The  rare antigen-positive  COS  cells were  selected on  goat 
anti-human  Ig coated panning plates (23, 24). Plasmids were re- 
covered by alkaline lysis and precipitation, and were electroporated 
back into bacteria. Bacteria transformed with plasmids recovered 
after the second round  of COS cell selection were cloned and 
amplified. DNA purified from individual clones was electroporated 
into COS cells and tested for the ability to confer expression of 
the 106-ligand by immunofluorescence. 
The  cDNA  encoding  the  106-1igand was  subdoned  into 
Bluescript and sequenced by the dideoxy chain termination method 
using fluorescent M13 primers and an ALF sequencer (Pharmacia, 
Piscataway, NJ). 
Immunoprecipitation.  Day 3 PMA/ionomycin activated MSAB 
cells were labeled with nsI using lactoperoxidase. Cell lysates were 
prepared by extracting  with I% NP-40 in TrisAaline containing 
protease inhibitors.  106-Ig and 4-1BB-Ig fusion proteins were in- 
cubated with the extracts, and the immune complexes were precipi- 
tated with goat anti-human conjugated Sepharose beads. The beads 
were eluted with SDS/ME sample buffer, and the eluent run on 
a 0.1%  SDS, 5-15% polyacrylamide gradient  gel (25). 
Costimulation Assays.  PBMC were isolated from healthy volun- 
teer donors by using Ficoll-Hypaque density gradients. CD4 + T 
cells were further purified by rosetting with neuraminidase-treated 
SRBC, removal of nylon wool adherent cells, and depletion of CD8 
(leu2a), CD16 (leulla),  and HLA-DR (L243) expressing cells by 
immunomagnetic  bead selection (Dynal). 10  s CD4 + T cells were 
cultured  per well in 96-well plates in AIM-V serum-free media 
(GIBCO BILL) at 37~  in a 8% CO2 humidified atmosphere. 
The cells were incubated in flat-bottom  plates in the presence of 
PMA, PHA, or soluble OKT3, and fixed COS-7 cells transfected 
with 106-ligand or empty pcDNA-I vector. COS cells were fixed 
at day 2 after transfection in 1% paraformaldehyde for 7 rain at 
25~  Wells were pulsed with  1 #Ci of [3H]thymidine for the 
final 18 h of culture and incorporated radioactivity was measured 
in a scintillation counter. Representative data are shown from four 
experiments using different donors. All results are expressed as mean 
cpm  _  SEM of triplicate cultures. 
Results and Discussion 
To screen for human 106/OX-40-1igand, a soluble 106Ag- 
Ig fusion protein (106-Ig) was constructed, and produced by 
transient transfections of COS-7 cells and harvesting super- 
natants.  Using  indirect  immunofluorescence,  screening  of 
freshly isolated PBMC revealed no staining with the 106-Ig. 
Trace  expression  was  noted  on  staining  PHA  or  PMA/ 
ionomycin activated T  cells and PMA/ionomycin activated 
B cells, with <4% positive cells (data not shown). Staining 
of fresh, adherent, PMA or IFN-3` activated monocytes was 
negative.  Screening of tumor lines revealed  that  the EBV- 
transformed B cell lines, MSAB and 9037, and a Burkitt lym- 
phoma, Jiyoye, demonstrated trace reactivity,  <5% positivity. 
However, after activation with PMA/ionomycin, the MSAB 
cell line dramatically increased its expression over 3-4 d, be- 
ginning on day 2 (Fig. 1 A). Subsequent rescreening of tumor 
cell lines after stimulation with PMA/ionomycin revealed that 
the monocytic cell line, THP-1, could also express ligand after 
3-4 d (Fig.  1 A). Immunoprecipitation of 12si surface-labeled 
activated MSAB cells with the 106-Ig fusion protein revealed 
a 32-kD  antigen,  with  a minor  band  at  60 kD  probably 
representing  a nonreduced dimer  (Fig.  1 B). 
Using a cDNA library prepared from day 3 PMA/iono- 
mycin activated MSAB cells,  106-Ig was used to select for 
cDNA clones that encode the 106-1igand.  After two rounds 
of expression,  immunoselection, and bacterial transformation, 
individual clones were isolated. Transfection of COS-7 cells 
with purified plasmid DNA from 3 out of 14 clones con- 
ferred high level expression of 106-Ig binding activity. This 
binding activity was shown to be specific, in that neither a 
soluble fc fragment  of Ig nor an irrelevant  fusion protein, 
4-1BB-Ig, bound transfectants  (Fig.  2 A). 
Sequencing the three 1-kb 106-1igand cDNAs revealed that 
all three encode the same protein.  This protein was found 
to be identical to gp34, an antigen previously known to be 
expressed only by HTLV-l-infected T cells, and reported to 
have  a  region  of homology with  t-lactate  dehydrogenase 
(26-28). The only difference between the 106-1igand and gp34 
cDNA clones is 101 bases of additional 5' untranslated region 
(UTR)  found in  two of the  106-1igand  dunes.  The  106- 
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ligand.  (A) Activated MSAB  and 
THP-1  cell lines.  Cells were acti- 
vated with 5 ng/ml PMA and 500 
ng/ml ionomycin and stained after 
72  h  of culture.  The  cells  were 
stained with Fc-lg, 4-1BB-Ig,  and 
106-Ig, followed by PE-conjugated 
goat anti-human Ig. (B) Immuno- 
precipitation of 106-1igand. Resting 
and  PMA/ionomycin  activated 
MSAB  cells  were  surface  labeled 
with lmI, and lysed in NP-40-con- 
taining buffer. Immune complexes 
were  generated  with  106-Ig  or 
4-1BB-Ig fusion proteins, and evalu- 
ated by SDS-PAGE on a reducing 
5-15%  gradient gel. 
ligand/gp34 cDNA encodes a 183 amino acid  (aa) polypeptide 
of the type II membrane configuration (Fig. 2 B). Alignment 
of the 133-aa extracellular domain with human TNF-ce re- 
veals 15% aa homology, and alignment with the emerging 
ligand family reveals primarily one core region of conserva- 
tion (Fig. 2 C). There is also a remarkable conservation of 
the hydrophobicity or charged nature of certain aa residues. 
Analysis of secondary structure as predicted by the Chou and 
Fasman (29) algorithm reveals a propensity to form a large 
amount of  beta structure. Also of  note in the deduced mRNA, 
is the presence of a 58-bp AU rich region in the 3' UTR, 
including two AUUUA elements.  Similar AU-rich motifs 
are frequently present  in cytokine mRNAs, and have been 
shown to confer instability  which is regulatable by cellular 
activation  (30). 
Cross-linking  of the  106/OX-40  antigen on CD4 + T 
cells with recombinant 106-1igand generated costimulatory 
signals. COS-7 cells transfected with the 106-1igand cDNA- 
containing plasmid (COS/106-1igand) and were paraformalde- 
hyde fixed and tested for their ability to costimulate prolifera- 
tion. Cultures of CD4 + T cells activated with submitogenic 
doses of PMA (Fig. 3 A), soluble anti-CD3 antibody (Fig. 
3 B), or submitogenic doses of PHA (Fig. 3 C), were indeed 
found to be costimulated  by COS/106-1igand cells and not 
by COS cells transfected  with empty  vector. Moreover, soluble 
106-Ig, but not 4-1BB-Ig, inhibited these responses (Fig. 3 D). 
The 106-Ig fusion proteins were used to stain the HTLV- 
1-transformed cell lines, MT-2 and HUT-102.  It is interesting 
to note that MT-2 cells stained brightly whereas HUT-102 
cells stained minimally. In contrast, staining these cell lines 
with the L106 antibody revealed  an inverted pattern of staining, 
in that MT-2 cells stained minimally and HUT-102 cells 
stained brightly (Fig. 4). HTLV-I-infected cell lines repre- 
sent the richest known sources of  nonrecombinant 106/OX- 
40  antigen and  106-1igand, and the reciprocal pattern of 
staining  suggests possible autocrine interactions. 
Using a soluble receptor construct (106-Ig) we have cloned 
a ligand for the 106/OX-40  antigen, and found it to be iden- 
tical to gp34. 106-1igand/gp34 expression is newly described 
as a late activation  antigen on the EBV-transformed B cell 
line, MSAB, and on the monocytoid cell line, THP-1, after 
stimulation with PMA/ionomycin. By staining with 106- 
Ig, high level 106-ligand  expression  was detected on the HTLV- 
I-infected cell line MT-2, the cell line from which gp34 was 
originally identified and cloned (26). gp34 is here newly de- 
scribed as a member of the TNF family, and is demonstrated 
to mediate functional effects upon binding the 106/OX-40 
antigen present  on activated CD4 + T  cells. 
The in vivo distribution of the 106-1igand/gp34 remains 
unclear. Previous work with the anti-gp34 antibodies revealed 
no positive cell source after staining  a broad panel of 106- 
ligand/gp34 on transformed or vitally infected cell lines of 
three hematopoietic  lineages, B cell, T cell, and monocytoid. 
However, staining  of resting or activated peripheral blood 
B cells, T cells, and monocytes  has yielded only trace positive 
staining. This extremely restricted pattern of expression of 
106-1igand suggests that there are stringent requirements for 
the activation of the 106-1igand/gp34 enhancer in nontrans- 
formed cells. Alternatively, the 106-1igand/gp34 could be ex- 
pressed primarily as a soluble molecule. It is interesting to 
note that the immunogen used to generate the first anti-gp34 
antibody was a glycoprotein fraction derived from the super- 
natant of MT-2 cells (26). In addition,  by dot blot we find 
evidence of soluble ligand in the supernatants of transfected 
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Figure  3.  Recombinant  106-1igand costimulates  the proliferation of 
CD4 + T cells. Proliferative response of purified CD4 + T cells after cul- 
ture for 5 d in the presence of:  (A) 2.5 ng/ml PMA  and a titration  of 
fixed COS/106-1igand (B) or COS/vector ([]); (B) 2 #g/ml sohble OKT3 
and a titration of fixed COS/106-1igand  (ll) or COS/vector (D); (C) 50 
ng/ml PHA and a titration of fixed COS/106-1igand  (I) or COS/vector 
([~);  (D)  50 ng/ml PHA,  2  x  104 fixed COS/106-ligand,  and either 
4-1BB-Ig (ll) or 106-Ig (A) fusion proteins, or 2  x  104 COS/vector  ([~). 
COS-7 cells (data not shown). However, these situations rep- 
resent instances  of either  pathological or contrived  overex- 
pression. 
With only 15% aa homology to TNF, and the substitu- 
tion of certain invariant aa residues described for the TNF/ 
ligand family, the 106-1igand/gp34 exhibits the greatest diver- 
gence of the reported TNF/ligand family members.  How- 
ever, this family of molecules is very diverse in terms of pri- 
mary sequence,  and other members exhibit low percentages 
of aa homology with TNF as well: CD27L,  -20%, CD30L, 
-16%, and 4-1BBL,  -16%. The family of molecules is related 
by the predicted formation of almost exclusively beta sheet- 
containing secondary structures in the extracellular domain, 
and by analogy with TNF,  they are predicted  to fold into 
Figure  2.  Expression and sequence analysis of recombinant 106-1igand. 
(.4) COS-7 cells were transfected with the 106-1igand cDNA or with ir- 
relevant CD4 cDNA, and were stained with fusion protein after 48 h of 
culture. COS cells transfected with the irrelevant cDNA were nonreactive 
with all fusion proteins (data not shown). (B) Sequence of the 106-ligand 
cDNA. A bracket demarks the 101 bases of additional 5' UTR, the trans- 
membrane is boxed, the four N-linked glycosyhtion sites are in small boxes, 
the 59 base AU rich region is marked by a pair of brackets, and the polyad- 
enylation signal is noted by a small box. (C) Alignment of the extracel- 
lular domain of TNF/ligand family. Conserved residues  or two nearly iden- 
tical hydrophobically  conserved residues  among the whole family are boxed, 
and residues shared  with 106-ligand/gp34  by TNF-ot or at least two other 
family  members  are  shaded. These  sequence  data are  available from 
EMBL/GenBank/DDBJ under accession number x79929. 
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Figure 4.  Expression  of 106-1igand and 106/human OX-40 antigen on 
FITLV-I-infected  cell lines. (A) MT-2 cells were stained with fusion pro- 
teins and goat anti-human Ig. (B) HUT-102  cells were stained with fusion 
a beta-jeUyroll conformation (6). The relationship of 106-1i- 
gand/gp34 to the previously described 70-kD mouse OX40-Ig 
binding protein expressed on peritoneal exudate B cells is un- 
known, as no cDNA for that antigen has been reported (31). 
Since the initial description of the rat OX-40 antigen as 
a marker specific for activated CD4 + T  cells (1),  and the 
finding that it is a NGFR/TNFR fam~y member (2), there 
has been much interest in the potential function of this mol- 
ecule.  Our studies demonstrate that the recombinant 106- 
ligand/gp34 interacts avidly with the human 106/OX-40 an- 
tigen and can induce potent costimulatory signals.  Because 
the 106-1igand/gp34  appears as a late activation antigen, we 
speculate that it may function to transmit a late costimulus, 
and to thereby promote the survival of activated CD4 + T 
cells, and prolong the immune response at sites of active ligand 
expression. 
proteins and goat anti-human lg. (C) MT-2 cells were stained with L106- 
PE or an irrelevant IgGI-PE. (D) HUT-102 cells were stained with L106- 
PE or an irrelevant IgG1-PE. 
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